Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

Inclusion Criteria

• •1. Over the age of 18 years old;
• •2. Tissue or cell pathological diagnosis of NSCLC;
• •3. Brain CT or MR validated BM;
• •4. Non-increased-intracranial-pressure symptomatic BM;
• •5. Haven't received TKI target treatment;
• •6. Haven't received brain radiotherapy;
• •7. Patients in initial treatment should be detected EGFR mutation;
• •8. Expected survival more than 6 months;
• •9. KPS no less than 70, or KPS less than 70 caused by paralysis due to recent brain metastases;
• •10. Liver and kidney function requirements: SGOT/SGPT≦2.5 times of the upper limit, Total bilirubin≦1.5 times of the upper limit, serum Creatinine≦1.5 times of the upper limit;
• •11. Routine blood test requirements: WBC≧3.0×109/L, NE≧1.8×109/L, PLT≧90×109/L，no requirement for Hb;
• •12. Blood glucose requirements: within the normal range, diabetic patients are receiving treatment and their glucose was being controlled in a steady state;
• •13. Female patients in childbearing age: HCG (-);
• •14. Patients signed an inform Consent.